Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Hikma Pharmaceuticals ( (GB:HIK) ).
Hikma Pharmaceuticals reaffirmed its full-year 2026 guidance after a strong start across its Injectables, Branded and Hikma Rx businesses, supported by robust demand, recent product launches and expanding manufacturing capacity. The company expects group revenue to grow 2% to 4% and operating profit to reach $720 million to $770 million, while maintaining solid margins in each division and winding down its non-core 503B compounding unit.
Management highlighted progress in complex inhalation platforms, including a new device partnership to accelerate its generic Ellipta programme and continued contribution from generic Advair Diskus, underscoring Hikma’s push into differentiated respiratory products. The board also reinforced its shareholder returns strategy with a 5% higher total dividend for 2025 and an ongoing share buyback of up to $250 million, even as it monitors Middle East geopolitical risks and rising logistics and energy costs.
The most recent analyst rating on (GB:HIK) stock is a Buy with a £1800.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.
Spark’s Take on HIK Stock
According to Spark, TipRanks’ AI Analyst, HIK is a Neutral.
The score is held back primarily by weakening cash generation and a notably bearish technical trend (oversold and trading below key moving averages). These are partially offset by attractive valuation (low P/E and strong dividend yield) and a constructive earnings-call outlook supported by guidance comfort and a GBP 250m buyback, despite near-term injectable headwinds.
To see Spark’s full report on HIK stock, click here.
More about Hikma Pharmaceuticals
Hikma Pharmaceuticals is a UK-headquartered multinational pharmaceutical group that develops, manufactures and markets a broad range of branded and non-branded generic medicines. With a strong presence in North America, the Middle East and North Africa and Europe, it focuses on injectables, branded products and prescription generics, leveraging local manufacturing, licensing partnerships and inhalation technology expertise.
Average Trading Volume: 1,412,508
Technical Sentiment Signal: Sell
Current Market Cap: £2.91B
See more data about HIK stock on TipRanks’ Stock Analysis page.